CRUK are currently looking for a highly motivated Senior Bioscientist to join the Drug Discovery Unit to provide assay development, screening and enzymology support to our oncology focused drug discovery programs. As part of a multi-disciplinary team, you will be responsible for the development and optimisation of novel biochemical assays, performing medium throughput screens and target-ligand mechanism of action studies for hit-to-lead drug discovery programmes. The postholder will be accountable for the design, execution, and interpretation of biochemical assays that support the discovery and characterization of novel anti-cancer drugs. The role would suit someone looking for the opportunity to support the day-to-day running of a busy drug discovery laboratory.
You should have a degree in a Biological discipline (or equivalent relevant experience) and have extensive experience across a wide range of biochemical assay screening platforms and technologies. Ideally a strong background in elucidating small molecule-protein interactions via mechanistic studies is desirable. You will be a self-motivated and organised individual with a conscientious and meticulous approach to working practices. A PhD and significant experience in academic drug discovery and / or in biotech or pharma would be an advantage.
The Drug Discovery Unit (DDU) was established in 2009 and has a strong record of candidate drug delivery with successful project collaborations with AstraZeneca, GSK and biotech partners as well as grant funding from CRUK, Wellcome and other charities. The DDU integrates medicinal, computational and synthetic chemistry with advanced biochemical and biophysical assays, in vitro cellular biology and in vivo capability. CRUK's laboratories are located in Alderley Park, Cheshire and are very well equipped. The unit has established facilities to enable state-of-the-art biological and clinical target assessment and validation, small molecule drug design and synthesis and the biological evaluation of the resultant compounds. The DDU builds upon fundamental biology discoveries made within the CRUK Manchester Institute to investigate novel drug discovery targets and to provide new chemical entities for the treatment of unmet clinical needs in cancer patients. The lab's current portfolio encompasses a variety of targets including projects targeting the cancer cell cycle control, tumour stromal regulation, cancer metabolism and suicide gene therapy.
The Cancer Research UK Manchester Institute (www.cruk.manchester.ac.uk), an Institute of The University of Manchester (www.manchester.ac.uk), is a world-leading centre for
excellence in cancer research. The Institute is core funded by Cancer Research UK
(www.cancerresearchuk.org), the largest independent cancer research organisation in the world. They are currently situated at the internationally-renowned life sciences campus at Alderley Park in Cheshire England, 15 miles from Manchester, a vibrant and dynamic city surrounded by beautiful countryside. CRUK are partnered with The Christie NHS Foundation Trust (adjacent to the CRUK MI Paterson Building) in South Manchester (www.christie.nhs.uk), one of the largest cancer treatment centres in Europe. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes.
To apply for this position please visit our website:
For any informal enquiries about this post, please contact Dr Graeme Thomson, email:
Application deadline: 13 May 2021
Application deadline: 13 May 2021
The EACR is grateful for the continued support of its Industry Partners: